SCHEMBL1383443

SCHEMBL1383443

Cc1cc(C(=O)Nc2cccc(OCc3ccccc3-c3ccccc3)c2)c(C)n1-c1ccccc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
KCNK3 O14649 2/20 0.43
KCNK9 Q9NPC2 2/20 0.43
MCL1 Q07820 1/20 0.42
S1PR1 P21453 3/20 0.42
TRPV4 Q9HBA0 4/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
S1PR3 Q99500 1/20 0.41
SGMS2 Q8NHU3 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
OPRL1 P41146 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1385014 0.92 SGMS2 (0.48) KCNK3KCNK9CNR1CNR2SGMS2
SCHEMBL1378540 0.90 KCNK3 (0.46) KCNK3KCNK9CNR1CNR2SGMS2
SCHEMBL1384200 0.89 KCNK3 (0.45) GAAKCNK3KCNK9CNR1CNR2
SCHEMBL1383266 0.89 POLB (0.45) GAAKCNK3KCNK9CNR1CNR2
SCHEMBL1382360 0.88 KCNK3 (0.44) KCNK3KCNK9CNR1CNR2SGMS2
SCHEMBL1381013 0.88 KCNK3 (0.44) KCNK3KCNK9CNR1CNR2SGMS2
SCHEMBL1379728 0.88 PDK1 (0.52) KCNK3KCNK9CNR1CNR2TAAR1
SCHEMBL1383682 0.88 KCNK3 (0.46) KCNK3KCNK9CNR1CNR2SGMS2
SCHEMBL1380790 0.88 POLB (0.44) GAAKCNK3KCNK9CNR1CNR2
SCHEMBL1381480 0.88 KCNK3 (0.46) KCNK3KCNK9CNR1CNR2SGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 2011-06-15 JP claimed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands EXELIXIS, INC. (US) 2011-06-16 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 KDM4E 4268/4885GAA 1346/4885KCNK3 3073/4885
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands NCOA1, NCOA2, NCOA3 KDM4E 1281/4885GAA 4341/4885KCNK3 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.